All In MedTech

FDA Clearance Tracker · P230013-S013

Edwards EVOQUE Tricuspid Valve Replacement System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 31, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 31, 2025

Approved

Time to decision

178 days

Received May 6, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P230013-S013
Device name
Edwards EVOQUE Tricuspid Valve Replacement System
Applicant location
Irvine, CA
Received
May 6, 2025
Decided
Oct 31, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P230013

Device type

Device class
Class III

Every decision under product code NPW

FDA's approval statement

As written in FDA's record.

Approval for a revision to the Instructions for Use to add the results of the Full Cohort of the TRISCEND II trial.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.